Levicept Looks For No Pain, More Gain With Osteoarthritis Offering
Executive Summary
The UK firm is weighing up its options for late-stage development of LEVI-04 after unveiling positive Phase II results of Phase II for the neurotrophin-3 inhibitor in moderate-to-severe osteoarthritis.